Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Treatment Outcomes and Molecular Prognostic Factors in TP53 Mutated Myeloid Neoplasms

13. november 2026 oppdatert av: Centre Hospitalier Universitaire de Nice

TP53-mutated myeloid neoplasms encompass biologically heterogeneous disorders with frequent cytogenetic abnormalities and poor outcomes. In myelodysplastic neoplasms, TP53 allelic state contributes to clinical phenotype and prognosis. In acute myeloid leukemia (AML) and myelodysplastic syndromes with excess blasts, molecular similarities support studying TP53-associated disease across conventional diagnostic boundaries, although pooling lower-risk and advanced diseases can introduce important clinical heterogeneity. Available therapies improve remission in some patients without reliably producing durable disease control. In a pooled analysis of poor-risk cytogenetic AML with TP53 mutations, azacitidine plus venetoclax increased remission compared with azacitidine alone without a corresponding improvement in survival. A recent molecular analysis of the pivotal CPX-351 trial found that benefit was concentrated in AML with myelodysplasia-related mutations rather than TP53-mutated AML. Allogeneic hematopoietic cell transplantation (HCT) can provide prolonged survival in selected patients, but its outcome depends on biological and clinical context. Retrospective transplant data support integrating VAF and cytogenetics, whereas biological-assignment data in MDS suggest that some patients with TP53 mutations benefit from transplantation. the investigators sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure. Our purpose was hypothesis generation rather than causal ranking of regimens or derivation of a validated transplant-selection rule.

Studieoversikt

Status

Har ikke rekruttert ennå

Studietype

Observasjonsmessig

Registrering (Antatt)

200

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

TP53 mutated AML and HR-MDS patients

Beskrivelse

Inclusion Criteria:

  • TP53 mutated myeloid AML (> 20% blasts) or HR-SMD
  • Age: Age ≥ 18 years
  • Allo-HCT was permitted.
  • Available NGS analysis at diagnosis
  • TP53 VAF > 2%
  • Myeloid sarcoma were permitted
  • Patients received at least 1 treatment line

Exclusion Criteria:

  • TP53 mutations class 1 or 2 or 3 (American College of Medical Genetic and Genomics
  • Patients alive at the start of the study who did not receive study information or who objected to the collection of data
  • TP53 CCUS or CHIP

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: RETROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
TP53 mutated myeloid neoplasms from Nice University Hospital

We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure

We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure

TP53 mutated myeloid neoplasms from Saint-Louis University Hospital

We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure

We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Description of clinical outcomes according to treatment patterns
Tidsramme: Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027

We sought to describe treatment patterns in fonction of outcomes in a pooled TP53-associated clinical cohort

Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
HCT as a time-dependent exposure.
Tidsramme: Time from date of diagnosis then HCT to date of relapse or death from any cause, assessed up to 01/01/2027

Description of transplanted patients to assess HCT as a time-dependent exposure.

Time from date of diagnosis then HCT to date of relapse or death from any cause, assessed up to 01/01/2027
Pre-HCT TP53 variant allelic frequency (VAF)
Tidsramme: Baseline

Variant allelic fraquency of TP53 at diagnosis

Baseline
Molecular prognostic
Tidsramme: Baseline

To explore survival impact of cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF

Baseline

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

1. juni 2027

Datoer for studieregistrering

Først innsendt

6. november 2026

Først innsendt som oppfylte QC-kriteriene

13. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere